Buenos Aires, Argentina (UroToday.com) Badrinath Konety, Professor University of Minnesota, discussed the diagnosis and treatment of high grade bladder cancer. Regarding diagnosis there are numerous biomarkers and adjuncts to traditional cystoscopy to aid in diagnosis.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Particularly, TRAIL and other inflammatory cytokines are used to tailor response to BCG. The CyPRIT cytokine panel has been developed to assess which patients are more likely to fail and represents AUC 0.85 predicting response to BCG. FISH and response to BCG and preforming prior to and after 6th dose of BCG and if positive becomes negative that indicates positive response to BCG. If the FISH remains positive or turns positive this is an ominous predictor for recurrent disease. Further research is needed to validate and incorporate these biomarkers into clinical practice.
World Urological Oncology Federation Symposium at the SIU Congress 2016 - October 20 - 23, 2016 – Buenos Aires, Argentina
Written By: Stephen B. Williams, M.D., Assistant Professor in Urology, The University of Texas Medical Branch, Galveston, TX. and Ashish Kamat, M.D. Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX.